Results 61 to 70 of about 2,921 (175)

The Impact of Oral‐Gut Microbiota Structure and Its Manipulation on RA Development and Management

Food Science &Nutrition, Volume 14, Issue 8, August 2026.
(A) Schematic representation of oral–gut microbiota composition in health and rheumatoid arthritis (RA), highlighting the enrichment of beneficial microorganisms (green) under healthy conditions and the expansion of pathogenic microorganisms (orange) in RA‐associated dysbiosis.
Parisa Ahmadi, Mahmoud Mahmoudi, Sina Mozaffari‐Jovin, Ramiar Kamal Kheder, Tola Abdulsattar Faraj, Samaneh Mollazadeh, Jafar Hajavi, Hanieh Kolahdooz, Seyed‐Alireza Esmaeili   +8 more
wiley   +1 more source

Anti‐Modified Protein Antibodies in Rheumatoid Arthritis: Pathogenic, Protective, or Passive Bystander?

Immunological Reviews, Volume 341, Issue 1, August 2026.
ABSTRACT The presence of anti‐modified protein antibodies (AMPA) is a hallmark of rheumatoid arthritis (RA). AMPA recognize post‐translationally modified proteins and are cross‐reactive. AMPA include anti‐citrullinated protein antibodies (ACPA), anti‐carbamylated protein antibodies (anti‐CarP), and anti‐acetylated protein antibodies (AAPA).
Amber‐Sarai F. L. Stalman, Diane van der Woude   +1 more
wiley   +1 more source

Secretion and expression of the Pasteurella haemolytica Leukotoxin

Journal of Bacteriology, 1990
The Pasteurella haemolytica leukotoxin gene cluster (lktCABD) is homologous to the Escherichia coli hemolysin locus (hlyCABD). Since the cloned leukotoxin (LktA) is not secreted from E. coli cells, a heteroplasmid complementation system was developed that permits secretion of the leukotoxin from cells expressing the hemolysin transport proteins HlyB ...
S K, Highlander, M J, Engler, G M, Weinstock   +2 more
openaire   +3 more sources

Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase [PDF]

Nature Medicine, 1997
Leukotoxin is a linoleic acic oxide produced by leukocytes and has been associated with the multiple organ failure and adult respiratory distress syndrome seen in some severe burn patients. Leukotoxin has been reported to be toxic when injected into animals intravenously.
Moghaddam, Mehran F., Grant, David F., Cheek, Jeffrey M., Greene, Jessica F., Williamson, Kristin C., Hammock, Bruce D.   +5 more
openaire   +2 more sources

The Extracellular Domain of the β₂ Integrin β Subunit (CD18) Is Sufficient for Escherichia coli Hemolysin and Aggregatibacter actinomycetemcomitans Leukotoxin Cytotoxic Activity

mBio, 2019
The Escherichia coli hemolysin (HlyA) is a pore-forming exotoxin associated with severe complications of human urinary tract infections. HlyA is the prototype of the repeats-in-toxin (RTX) family, which includes LtxA from Aggregatibacter ...
Laura C. Ristow, Vy Tran, Kevin J. Schwartz, Lillie Pankratz, Andrew Mehle, John-Demian Sauer, Rodney A. Welch   +6 more
doaj   +1 more source

Tracking COVID‐19 Severity and Progression Through Amines and Lipid Mediators

Journal of Medical Virology, Volume 98, Issue 7, July 2026.
ABSTRACT Coronavirus disease 2019 (COVID‐19) exhibits a broad spectrum of severity, ranging from mild to critical cases. To reduce mortality and costs, tailored early interventions for at‐risk patients are essential. This study elucidates the association between longitudinal metabolomic profiles and COVID‐19 severity and progression.
Melissa Goris, Merys Valdez, Lieke Lamont, Wei Yang, Amy Harms, Naama Karu, Sabine Bos, Jelte Geerlings, Tom Ottenhoff, Roula Tsonaka, Anna HE Roukens, M. Sesmu Arbous, Simone A. Joosten, Thomas Hankemeier, Alida Kindt, In collaboration with BEAT‐COVID group, M.S. Arbous, B.M. van den Berg, S. Cannegieter, C.M. Cobbaert, A. van der Does, J.J.M. van Dongen, J. Eikenboom, M.C.M. Feltkamp, A. Geluk, J.J. Goeman, M. Giera, T. Hankemeier, M.H.M. Heemskerk, P.S. Hiemstra, C.H. Hokke, J.J. Janse, S.P. Jochems, S.A. Joosten, M. Kikkert, L. Lamont, J. Manniën, T.H.M. Ottenhoff, M.R. del Prado, N. Queralt Rosinach, M. Roestenberg, M. Roos, A.H.E. Roukens, H.H. Smits, E.J. Snijder, F.J.T. Staal, L.A. Trouw, R. Tsonaka, A. Verhoeven, L.G. Visser, J.J.C. de Vries, D.J. van Westerloo, J. Wigbers, H.J. van der Wijk, R.C. van Wissen, M. Wuhrer, M. Yazdanbakhsh, M. Zlei   +57 more
wiley   +1 more source

Periodontitis and Periodontal Conditions in Systemically Healthy Children and Adolescents

Journal of Clinical Periodontology, Volume 53, Issue 7, Page 1100-1198, July 2026.
ABSTRACT Objective To answer the PICoS question ‘in systemically healthy children and adolescents (Population), what are the main features of periodontitis, necrotising periodontal diseases (NPD) and other periodontal conditions (periodontal abscesses, endo‐periodontal lesions, traumatic occlusal forces, prosthesis‐ and tooth‐related factors ...
Inbar Eshkol‐Yogev, Nagore Ambrosio, Cheryl Somani, Elena Figuero, Lior Shapira, Janet Davies   +5 more
wiley   +1 more source

CCR5 is a receptor for Staphylococcus aureus leukotoxin ED [PDF]

Nature, 2012
Pore-forming toxins are critical virulence factors for many bacterial pathogens and are central to Staphylococcus aureus-mediated killing of host cells. S. aureus encodes pore-forming bi-component leukotoxins that are toxic towards neutrophils, but also specifically target other immune cells.
III, Francis Alonzo, Kozhaya, Lina, Rawlings, Stephen A., Reyes-Robles, Tamara, DuMont, Ashley L., Myszka, David G., Landau, Nathaniel, Unutmaz, Derya, Torres, Victor J.   +8 more
openaire   +2 more sources

Identification of a novel Staphylococcus aureus two-component leukotoxin using cell surface proteomics. [PDF]

PLoS ONE, 2010
Staphylococcus aureus is a prominent human pathogen and leading cause of bacterial infection in hospitals and the community. Community-associated methicillin-resistant S.
Christy L Ventura, Natalia Malachowa, Carl H Hammer, Glenn A Nardone, Mary Ann Robinson, Scott D Kobayashi, Frank R DeLeo   +6 more
doaj   +1 more source

From the Proteome to Therapeutics: A Multi‐Database Approach to Drug Discovery in Periodontitis—An Exploratory Pilot Study

Journal of Clinical Periodontology, Volume 53, Issue 7, Page 990-1004, July 2026.
ABSTRACT Introduction This explanatory pilot study presents a workflow to identify approved drugs, which could be repurposed for periodontitis therapy using salivary proteomics combined with drug‐target database screening. Methods Proteomic analyses of saliva using LC–MS/MS were conducted in two independent settings: a cohort (sub‐study I, N = 187) and
Taisir Bozo, Annette Murr, Birte Holtfreter, Sebastian‐Edgar Baumeister, Peter Meisel, Uwe Völker, Werner Weitschies, Henry Völzke, Philipp Kanzow, Elke Hammer, Manuela Gesell Salazar, Thomas Kocher   +11 more
wiley   +1 more source